The Tufts ECOG Network is a unified group of hospitals dedicated to improving the care of cancer patients through the entry of patients onto clinical trials. The Tufts Group has provided increasing accrual onto clinical trials and increasing scientific input to ECOG. Our Network has grown consistently in the past, there are 22 affiliated hospitals in Massachusetts, Rhode Island and Connecticut. This provides us with the ability to have a strong impact upon the care of patients in New England. The Tufts Network is unique because its major components are three of the main teaching hospitals for medical schools in New England. This prevalence of academia in the Group providing the Tufts Network with incomparable capability to be a significant contributor to the development of the basic science necessary for clinical cancer research. The leaders of the Tufts Network; Dr. Thomas J. Smith and Dr. Nicholas Robert have positions of leadership in the ECOG, providing direction to the Group. Their interest in clinical trials has provided the impetus for the growth of clinical research both at New England Medical Center and across the Tufts Network.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA007190-31
Application #
2084566
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-12-01
Project End
1999-04-30
Budget Start
1994-08-10
Budget End
1995-04-30
Support Year
31
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Tufts University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02111
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Ganz, Patricia A; Land, Stephanie R; Geyer Jr, Charles E et al. (2011) Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 29:1110-6
Swain, Sandra M; Jeong, Jong-Hyeon; Geyer Jr, Charles E et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-65
Landry, Jerome; Catalano, Paul J; Staley, Charles et al. (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101:587-92
Hughes, Lorie L; Wang, Molin; Page, David L et al. (2009) Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:5319-24
Horn, Leora; Dahlberg, Suzanne E; Sandler, Alan B et al. (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006-11
Greenberg, Peter L; Sun, Zhuoxin; Miller, Kenneth B et al. (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393-400
Souphron, Judith; Waddell, M Brett; Paydar, Amir et al. (2008) Structural dissection of a gating mechanism preventing misactivation of ubiquitin by NEDD8's E1. Biochemistry 47:8961-9
Burtness, Barbara; Goldwasser, Meredith A; Flood, William et al. (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-54

Showing the most recent 10 out of 30 publications